Skip to Content
Merck
  • Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders.

Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders.

Phlebology (2012-02-22)
S Rathbun, A Norris, J Stoner
ABSTRACT

Endovenous foam sclerotherapy (EFS) is used widely throughout the USA for the treatment of venous disorders. The purpose of the quantitative meta-analysis was to systematically and comprehensively evaluate the literature to provide accurate estimates of safety and efficacy outcomes for this procedure. A comprehensive electronic search of published literature in several databases was performed using a wide variety of MESH headings. In addition, meeting abstracts and bibliographies of selected references were reviewed for eligible papers. Two reviewers abstracted selected treatment-related data. Of 684 identified manuscripts and abstracts reviewed, 104 papers were abstracted and analysed. More than 50% were published between 2004 and 2008. EFS was found to be effective with similar vein occlusion rates to laser therapy, but less effective than surgery. In addition, major adverse effects were rare. EFS is a safe and effective therapy for the treatment of venous disorders.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Brij® L23 solution, 30 % (w/v) in H2O
Sigma-Aldrich
Tetradecyl sulfate sodium salt, 95%
Sigma-Aldrich
Decaethylene glycol mono­dodecyl ether, nonionic surfactant
Sigma-Aldrich
Thesit®, for membrane research
Sigma-Aldrich
ECO BRIJ® L4, average Mn ~362
Sigma-Aldrich
ECO Brij® L23
Sigma-Aldrich
Brij® L4, average Mn ~362
Sigma-Aldrich
Brij® L23, main component: tricosaethylene glycol dodecyl ether
Sigma-Aldrich
Brij® L23, suitable for Stein-Moore chromatography